New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|February 19, 2020
Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
Advertisement
Aaron Gerds, MD, assistant professor of Medicine, Cleveland Clinic - Taussig Cancer Center, discussed the results of a phase II BELIEVE study of luspatercept (Reblozyl) as treatment of patients with myelofibrosis-associated anemia.
Every cohort in the study had responses to treatment with luspatercept. Additionally, luspatercept successfully reduced the transfusion burden in 21.4% of the study subjects compared only 4.5% of those who received placebo, meeting the primary end point of the study.
Gerd notes, however, that responses were higher in patients who received ruxolitinib (Jakafi) along with the luspatercept.
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Tovecimig Submission for Biliary Tract Cancer Is Proceeding Despite FDA Request for New Trial
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5